White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April (opens original article in a new tab)

White House denies President Trump was the patient who received early access to an experimental weight loss drug, stating the application was not for him. Retatrutide is still under review and only used in clinical trials. Trump previously had early access to a Covid treatment.

• White House denies that President Trump was the patient who received early access to retatrutide
• Retatrutide is an experimental weight loss drug under federal review and only used in clinical trials
• Trump previously received early access to a Covid antibody treatment before approval